The first peer-reviewed results of Phase 1 and Phase 2 clinical trials of Russia’s coronavirus vaccine, which is named Sputnik-V, have been published in the medical journal The Lancet on Friday.
Results from the two 42 day trials which each included 38 healthy adults “have a good safety profile with no serious adverse events” among participants, The Lancet said in a press release, noting that the vaccine induced antibody responses in all participants.
Russia faced criticism last month when it announced the world's first approved coronavirus vaccine for public use, even before Phase 3 trials are completed.
Russia also faced skepticism over how quickly the vaccine was registered and the initial lack of scientific data around the clinical trials.
Naor Bar-Zeev, deputy director of the International Vaccine Access Center at Johns Hopkins University said in a linked comment that the studies are “encouraging but small,” according to The Lancet.
Bar-Zeev was not involved in the Russian study, but peer reviewed it.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) funding the vaccine development said the trial results confirm the "high safety and efficacy" of the vaccine, adding in a statement Friday that the results are "a powerful response to sceptics who unreasonably criticized the Russian vaccine."
Latest Stories
-
Ghana and Seychelles strengthen bilateral ties with focus on key sectors
3 mins -
National Elections Security Taskforce meets political party heads ahead of December elections
6 mins -
Samsung’s AI-powered innovations honored by Consumer Technology Association
26 mins -
Fugitive Zambian MP arrested in Zimbabwe – minister
44 mins -
Town council in Canada at standstill over refusal to take King’s oath
55 mins -
Trump picks Pam Bondi as attorney general after Matt Gaetz withdraws
1 hour -
Providing quality seeds to farmers is first step towards achieving food security in Ghana
1 hour -
Thousands of PayPal customers report brief outage
1 hour -
Gary Gensler to leave role as SEC chairman
2 hours -
Contraceptive pills recalled in South Africa after mix-up
2 hours -
Patient sues Algerian author over claims he used her in novel
2 hours -
Kenya’s president cancels major deals with Adani Group
2 hours -
COP29: Africa urged to invest in youth to lead fight against climate change
2 hours -
How Kenya’s evangelical president has fallen out with churches
3 hours -
‘Restoring forests or ravaging Ghana’s green heritage?’ – Coalition questions Akufo-Addo’s COP 29 claims
3 hours